Sepsis play Critical Pressure raises L10M series A

Critical Pressure Ltd. (Cambridge, U.K.) raised £10 million ($13.1 million) on Nov. 15 in a series A round from Medicxi. The company is developing CPL001 to treat severe sepsis. The inhibitor of dimethylarginine dimethylaminohydrolase1 (DDAH1) is slated to enter the clinic in early 2019. The compound was discovered at University College London in a project funded by the Wellcome Trust.

Critical Pressure was co-founded by James Leiper, a professor of molecular medicine at the University of Glasgow, and Simon Lambden, a lecturer in intensive care medicine at the University of Cambridge. Medicxi’s David Grainger is executive chairman of the newco...